Dr. Sukhmani K. Padda, an assistant professor of medicine at Stanford University, discusses emerging therapeutic strategies for several rare mutations in NSCLC including ROS1.

http://www.onclive.com/conference-coverage/mlcc-2018/novel-agents-emerging-for-lesserknown-targets-in-nsclc?p=1